Amrutanjan Health Care Ltd
Amrutanjan Health Care Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Amrutanjan Health Care Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Overall Financial Performance Q1 FY26 vs Q1 FY25: - Net Sales: Rs. EBITDA/profit before tax (PBT) for Q1 FY26: Rs.
From Amrutanjan Health Care Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Overall Financial Performance Q1 FY26 vs Q1 FY25:
- Net Sales: Rs. 94.05 Cr, up 12.31% from Rs. 83.74 Cr
- Gross Sales: Rs. 107.19 Cr, up 14.58% from Rs. 93.55 Cr
- Profit Before Tax: Rs. 11.29 Cr, up 77.80% from Rs. 6.35 Cr
- Profit After Tax: Rs. 8.31 Cr, up 79.87% from Rs. 4.62 Cr
- Category-wise Sales Growth:
- OTC Gross Sales: Rs. 96.79 Cr, up 20.19% from Rs. 80.53 Cr
- Comfy Gross Sales: Rs. 30.59 Cr, up 10.75% from Rs. 27.62 Cr
- Beverages Gross Sales: Rs. 9.69 Cr, down from Rs. 12.88 Cr (decline)
- Electro Plus Sales: Rs. 8.70 Cr, down from Rs. 10.44 Cr (decline)
- Volume Growth:
- Pain Management head ache care segment back to double-digit volume growth; Head category volume growth 6.8% YoY; Body category volume growth 24.6% YoY.
- Roll on category growing with market leadership; competition entry shows category attractiveness.
- Outlook:
- Focus on increasing operating profit margin (EBIT) from 11.44% to 13% by revenue growth and operational efficiency.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q1 FY26 results?
Overall Financial Performance Q1 FY26 vs Q1 FY25: - Net Sales: Rs. EBITDA/profit before tax (PBT) for Q1 FY26: Rs.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
The investor presentation for the quarter ended 30th June 2025 does not mention any capex, capacity expansion, or new plant/project details including amounts, status, or timelines.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.